On April 22, China’s gene sequencing listed company Bgi Genomics Co.Ltd(300676) (hereinafter referred to as ” Bgi Genomics Co.Ltd(300676) “, Bgi Genomics Co.Ltd(300676) ) released its annual report for 2021. The annual Bgi Genomics Co.Ltd(300676) operating revenue of last year was 6.766 billion yuan, a decrease of 19.42% compared with the same period of last year (year-on-year); The net profit attributable to shareholders of listed companies was 1.462 billion yuan, a year-on-year decrease of 30.08%; The basic earnings per share was 3.56 yuan, a year-on-year decrease of 32.13%.
Regarding the operation during the reporting period, Bgi Genomics Co.Ltd(300676) said that the company took the initiative to strategically adjust the product structure and supply chain strategy related to covid-19, continued to focus on the main business, continued to increase R & D investment, and accelerated the increase of global market share. The overall operating revenue of the company decreased compared with the base of the sudden and substantial increase of covid-19 epidemic in the same period of last year. The report also said that excluding the changes of covid-19 business, the company’s conventional business maintained a steady development trend.
In addition, in 2021, the total amount of Bgi Genomics Co.Ltd(300676) R & D investment was 542 million yuan, accounting for 8.01% of the operating revenue in the same period. Previously, in 2020, the total amount of R & D investment was 626 million yuan.
Quarterly, the operating revenue of Bgi Genomics Co.Ltd(300676) each quarter was 1.563 billion yuan, 2.083 billion yuan, 1.506 billion yuan and 1.614 billion yuan respectively, and the net profit attributable to listed shareholders was 525 million yuan, 561 million yuan, 328 million yuan and 473 million yuan respectively.
In terms of products, nearly half of the revenue before covid-19 came from reproductive health basic research and clinical application services. Last year, the annual revenue of such products was 1.192 billion yuan, an increase of 1.24% year-on-year, accounting for 17.62% of the total revenue; The revenue of cancer prevention and control and translational medicine services was 379 million yuan, an increase of 8.12% year-on-year, accounting for 5.61% of the total revenue; The revenue of basic research and clinical application services for infection prevention and control was 1.158 billion yuan, with a year-on-year increase of 73.01%, accounting for 17.12% of the total revenue; The revenue of multi group big data service and synthesis business was 642 million yuan, with a year-on-year increase of 2.50%, accounting for 9.48% of the total revenue; The revenue of comprehensive solutions for precision medical testing was 3.382 billion yuan, a year-on-year decrease of 39.20%, accounting for 49.99% of the total revenue; Other business income was 117464 million yuan, a year-on-year increase of 13.96%, accounting for 0.17% of the total revenue.
In the past 2021, Bgi Genomics Co.Ltd(300676) accounted for 42.63% of total revenue in mainland China, accounting for 57.37% of revenues in Europe and Africa, the United States, Asia (including Chinese mainland, Hong Kong, Macao and Taiwan) and Oceania.
In terms of R & D layout of covid-19 products, during the reporting period, Bgi Genomics Co.Ltd(300676) for the market demand of multi joint detection, rapid detection of nucleic acid, detection of different mutants, antigen self-test and so on, increased the investment in R & D resources and international qualification application, and the relevant detection kits have obtained the EU CE access qualification. The report said that at present, the company has formed a multi product coverage system including virus sequencing, nucleic acid detection, nucleic acid rapid detection, antigen rapid detection, antigen self-test, antibody rapid detection and neutralizing antibody detection.
It is worth mentioning that as of the end of the reporting period, Bgi Genomics Co.Ltd(300676) covid-19 testing products have covered more than 180 countries and regions around the world, and nearly 100 “fire eye” laboratories have been launched overseas, distributed in more than 30 countries and regions around the world. Among them, in terms of anti epidemic comprehensive solution services, Bgi Genomics Co.Ltd(300676) last year landed in the “eye of fire” Laboratory of the airport in Ethiopia and Saudi Arabia respectively to meet the service demand for rapid detection of cross-border personnel.
The controlling shareholder of Bgi Genomics Co.Ltd(300676) is Shenzhen Bgi Genomics Co.Ltd(300676) Technology Co., Ltd., with a shareholding ratio of 35.94%; The actual controller of the company is Wang Jian. Headquartered in Shenzhen, China, it has branches and medical laboratories in major Chinese cities such as Beijing, Tianjin, Wuhan, Shanghai and Guangzhou, as well as overseas centers and core laboratories in Europe, the Americas and the Asia Pacific.
The company’s main business is to provide genomics testing and research services for medical institutions, scientific research institutions, enterprises and institutions through gene testing, mass spectrometry, biological information analysis and other means. The main products include basic research and clinical application services of reproductive health, including nifty (noninvasive prenatal gene testing / fetal chromosome aneuploidy testing), cancer prevention and control and translational medicine services, basic research and clinical application services of infection prevention and control, multi omics big data services and synthesis business, comprehensive solutions for precision medical testing, etc.
According to the report, the company’s business has covered more than 100 countries and regions around the world, including more than 2000 scientific research institutions and more than 2300 medical institutions in China, including more than 500 third-class hospitals; More than 3000 overseas medical and scientific research institutions have cooperated in Europe, America, Asia Pacific and other regions, and have established cooperative relations with health authorities in more than 30 countries and regions to build a point line surface government business relationship network layout.
